Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

11 of 15 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

Alliance 1

No dated milestone in 2025 to 2030

ECOG-ACRIN 1

No dated milestone in 2025 to 2030

GEINO 1

TuvusertibPhase 2
No dated milestone in 2025 to 2030

German Cancer Research Center 1

No dated milestone in 2025 to 2030

Hospices Civils de Lyon (OLAGLI) 1

OlaparibPhase 2
No dated milestone in 2025 to 2030

Hutchmed 1

No dated milestone in 2025 to 2030

National Cancer Institute 1

NivolumabPhase 2
No dated milestone in 2025 to 2030

Nuvation Bio 1

FDA Fast Track granted, Aug 20, 2026

Rigel 1

No dated milestone in 2025 to 2030

Servier 1

VorasidenibApproved
No dated milestone in 2025 to 2030

University of Pennsylvania (Stephen Bagley) 1

No dated milestone in 2025 to 2030